Cardiovascular Clinical Studies

This channel includes news and new technology innovations from cardiovascular clinical trials. These clinical studies include all cardiac subspecialties.

a late breaking abstract describing dose response data from its positive Phase 2 clinical study of istaroxime in early cardiogenic shock (SEISMiC) will be presented on October 2 at the Heart Failure Society of America Annual Scientific Meeting in Washington, DC.

News | Cardiogenic Shock

Windtree Therapeutics Announces Istaroxime Late Breaker Abstract from its Positive Phase 2 Study in Early Cardiogenic Shock (SEISMiC) to be Presented at Heart Failure Society of America

September 27, 2022 — Windtree Therapeutics, Inc., a biotechnology company focused on advancing multiple late-stage ...

September 27, 2022

UC San Diego researchers have created the first diagnostic tool able differentiate between two similar pediatric inflammatory conditions, using a novel artificial intelligence-guided algorithm

News | Coronavirus (COVID-19)

How to Tell the Difference between Kawasaki Disease and MIS-C

September 26, 2022 — Kawasaki disease (KD) is the leading cause of acquired heart disease in children in developed ...

September 26, 2022

Evolut FX TAVR System Adds Innovative Features to Enhance Ease-of-Use and Predictable Valve Deployment

News | Structural Heart

Medtronic Announces FDA Approval of Next-Gen TAVR System for Treatment of Symptomatic Severe Aortic Stenosis

September 26, 2022 — Medtronic plc, a global leader in medical technology, announced U.S. Food and Drug Administration ( ...

September 26, 2022

Study of the Paradise Ultrasound Renal Denervation System Shows Significant Reduction in Blood Pressure in Patients with Uncontrolled Hypertension

News | Hypertension

ReCor Medical Announces Results of RADIANCE II Pivotal Trial at TCT 2022 Annual Meeting

September 26, 2022 — ReCor Medical, Inc., a wholly owned subsidiary of Otsuka Medical Devices Co., Ltd., announced the ...

September 26, 2022

EMPOWER CAD is the First Prospective, Female-Only Study of Coronary Interventions

News | Womens Cardiovascular Health

Shockwave Medical Initiates All-Female Coronary IVL Study

September 21, 2022 — Shockwave Medical, Inc., a pioneer in the development of Intravascular Lithotripsy (IVL) to treat ...

September 21, 2022

Abiomed (ABMD) announces the result of a three-year, investigator-led study of all Impella-supported patients treated at 109 hospitals in Japan shows a 30-day survival rate of 77% for patients with cardiogenic shock due to myocarditis.

News | Cardiogenic Shock

Multi-Center, Multi-Society Study of Impella-supported Patients with Cardiogenic Shock due to Myocarditis in Japan Achieves 30-day Survival of 77%

September 22, 2022 — Abiomed (ABMD) announces the result of a three-year, investigator-led study of all Impella ...

September 22, 2022

Results of the CLASP IID Trial Presented at TCT and published simultaneously in JACC: Cardiovascular Interventions

News | Structural Heart

Novel TEER Repair Device Meets Primary Endpoint in Treating Degenerative Mitral Regurgitation in Patients Not Eligible for Surgery

September 20, 2022 — Results of the first randomized controlled trial to directly compare two contemporary transcatheter ...

September 20, 2022

Dr. Gagan Singh, Dr. Susheel Kodali, and Dr. Azeem Latib with principal investigator, Dr. Adrian Ebner, following the initial first-in-human cases with the Supira System.

News | Cardiogenic Shock

Supira Medical Announces Successful First-in-Human Use of its Next Generation Percutaneous Ventricular Assist Device

September 19, 2022 — Supira Medical, Inc., a Shifamed portfolio company focused on developing the next-generation ...

September 19, 2022

Results also demonstrate the benefits for patients of Abbott's TriClip™ for tricuspid regurgitation, Amulet™ for atrial fibrillation and Portico™ for aortic stenosis

News | Structural Heart

Late-Breaking Data Show Breadth of Abbott's Minimally Invasive Structural Heart Technologies

September 17, 2022 — Abbott today announced data from five late-breaking presentations showing the benefits of its ...

September 17, 2022

Pathological Findings Confirm Importance of Early Detection and Treatment of Thrombus on Valve Leaflets

News | Structural Heart

First-ever Comparison of MicroCT and Histology in Self-expanding Transcatheter Aortic Valve Replacement Patients with Hypo-attenuated Leaflet Thickening

September 17, 2022 — Medtronic today announced findings from its Pathological Study of Hypo-Attenuated Leaflet ...

September 17, 2022

The Impella CP with SmartAssist heart pump is a minimally invasive, temporary heart pump that uses real-time intelligence associated with improved survival and heart recovery. (Graphic: Business Wire)

News | Hemodynamic Support Devices

Unloading with Impella for 30 Minutes Before PCI Associated with Reduced Infarct Size in STEMI Patients

September 17, 2022 — Results of a new per-protocol analysis of the ST-segment Elevation Myocardial Infarction Door-To ...

September 17, 2022

Results from largest randomized TAVR trial to date presented at TCT 2022

News | Embolic Protection Devices

Late-Breaking Data from PROTECTED TAVR Trial Demonstrate Reduced Risk of Disabling Stroke, Low Complication Rate with SENTINEL Cerebral Protection System

September 17, 2022 — Boston Scientific Corporation has announced results from the PROTECTED TAVR clinical trial ...

September 17, 2022

Edwards Lifesciences Corporation, today announced the company's PASCAL Precision transcatheter valve repair system for transcatheter edge-to-edge repair (TEER) has received FDA approval for the treatment of patients with degenerative mitral regurgitation (DMR).

News | TCT

Edwards Pascal Precision Transcatheter Valve Repair System Receives FDA Approval for Degenerative Mitral Regurgitation

September 16, 2022 — Edwards Lifesciences Corporation, today announced the company's PASCAL Precision transcatheter ...

September 16, 2022

Results from Largest Ever Real-World Evaluation of the MANTA Device Demonstrated Safety and Effectiveness with Low Complication Rates and a Short Learning Curve

News | Vascular Closure Devices

Co-Author of the Karolinska 1000 Consecutive MANTA Vascular Closure Device Study to Present Learnings at the Transcatheter Cardiovascular Therapeutics (TCT) 2022 Conference

September 16, 2022 — Teleflex Incorporated, a leading global provider of medical technologies, announced that Dr. Magnus ...

September 16, 2022

RECOVER IV is an on-label, two arm RCT that is designed to provide the clinical evidence needed to achieve a Class I guideline recommendation for Impella use in AMI cardiogenic shock.

News | Cardiogenic Shock

FDA Approves RECOVER IV Randomized Controlled Trial with Exception from Informed Consent (EFIC)

September 16, 2022 — Abiomed announced two approvals from the U.S. Food and Drug Administration (FDA) related to ...

September 16, 2022